Nedosiran

Drug Overview

In the specialized field of hematology and metabolic medicine, managing rare genetic disorders requires highly precise interventions to prevent systemic damage. Nedosiran is a breakthrough medication belonging to the siRNA (small interfering RNA) drug class. It represents a significant advancement for patients dealing with Primary Hyperoxaluria (PH), a condition that can lead to devastating consequences for the kidneys and, eventually, the entire blood-forming system.

As a highly advanced BIOLOGIC and TARGETED THERAPY, nedosiran is designed to “silence” specific genetic instructions in the liver. By doing so, it stops the overproduction of oxalate at its source. This prevents the formation of toxic crystals that can otherwise lead to kidney failure and a rare but severe hematologic complication known as systemic oxalosis, where crystals deposit in the bone marrow and disrupt healthy blood cell production.

• Generic Name: Nedosiran
• US Brand Names: Rivfloza
• Route of Administration: Subcutaneous (under the skin) injection
• FDA Approval Status: FDA-approved (October 2023) for the treatment of Primary Hyperoxaluria Type 1 (PH1) in children 9 years and older and adults with relatively preserved kidney function.

What Is It and How Does It Work? (Mechanism of Action)

Nedosiran functions as a TARGETED THERAPY using RNA interference (RNAi) technology. At the molecular and hematological level, its mechanism of action is highly specific:

1. Gene Silencing: Nedosiran consists of double-stranded siRNA conjugated to a sugar molecule (GalNAc) that specifically targets liver cells. Once inside the liver, it identifies the messenger RNA (mRNA) responsible for producing the enzyme Lactate Dehydrogenase (LDH).
2. Enzyme Reduction: By destroying this specific mRNA, nedosiran prevents the liver from producing the LDH enzyme. LDH is the “final step” enzyme that converts glyoxylate into oxalate.
3. Oxalate Suppression: With less LDH enzyme available, the liver’s production of oxalate drops significantly.
4. Hematological Protection: In advanced stages of the disease, oxalate levels in the blood can become so high that they crystallize in the bone marrow (systemic oxalosis). These crystals can physically crowd out blood-forming stem cells, leading to severe anemia, low white blood cell counts, and hemorrhage risk due to low platelets. By lowering oxalate production, nedosiran protects the bone marrow environment and ensures the continuity of healthy blood cell production.

FDA-Approved Clinical Indications

Primary Indication

In the hematology and nephrology drug categories, nedosiran is specifically indicated to lower urinary oxalate levels in children 9 years of age and older and adults with Primary Hyperoxaluria Type 1 (PH1) who have relatively preserved kidney function (usually an estimated glomerular filtration rate or eGFR of 30 mL/min/1.73 m2 or higher).

Other Approved & Off-Label Uses

While PH1 is the primary focus, the medical community is exploring the broader utility of nedosiran:

• Primary Hyperoxaluria Type 2 and 3: While not yet the primary focus of the current FDA label for all ages, clinical research has investigated the efficacy of nedosiran in these subtypes because the LDH enzyme is involved in oxalate production across all forms of PH.
• Systemic Oxalosis Management: Off-label use in patients with early signs of bone marrow crystal deposition to prevent progressive marrow failure.

Dosage and Administration Protocols

Nedosiran is administered as a monthly subcutaneous injection. The dosage is determined by the patient’s body weight to ensure optimal efficacy and safety.

Important Adjustments:

• Missed Doses: If a dose is missed, it should be administered as soon as possible. If the missed dose is not given within 7 days, it should be skipped, and the next dose should be taken at the next regularly scheduled time.
• Renal Insufficiency: Nedosiran is currently approved for patients with an eGFR of 30 or higher. For patients with severe kidney disease or those on dialysis, safety and efficacy have not yet been fully established in the primary labeling.
• Administration Sites: Injections should be rotated between the abdomen, upper thighs, or the back of the upper arms.

Clinical Efficacy and Research Results

Current clinical study data (spanning 2020-2026) has demonstrated the robust efficacy of nedosiran. The pivotal PHYOX 2 clinical trial provided the foundational data for its approval.

In this trial, patients receiving nedosiran showed a significant reduction in 24-hour urinary oxalate levels compared to those receiving a placebo. Medical generalizations from the trial data indicate that a substantial majority of patients achieved at least a 30% reduction in oxalate levels, with many reaching “normal” or “near-normal” ranges within six months of starting therapy. Furthermore, research showed that the reduction in oxalate was sustained over long-term follow-up (PHYOX 3 extension study), providing a reliable TARGETED THERAPY option for preventing the progression toward kidney failure and systemic oxalosis.

Safety Profile and Side Effects

Black Box Warning

There is currently no Black Box Warning for nedosiran.

Common side effects (>10%)

• Injection site reactions (redness, pain, itching, or swelling at the site of the shot).

Serious adverse events

• Hypersensitivity: Although rare, some patients may experience allergic reactions to the BIOLOGIC components.
• Abnormal Liver Function: Some patients may show temporary elevations in liver enzymes, though this was rarely a cause for stopping treatment in clinical trials.

Management Strategies

Injection site reactions are typically mild and self-limiting. Rotating the injection site and ensuring the medication is at room temperature before injection can help. If a patient develops signs of a severe allergic reaction (hives, difficulty breathing), they should seek immediate medical attention. Liver enzymes should be monitored periodically as part of routine care.

Research Areas

Current research is focused on the long-term impact of nedosiran on “stone burden” and bone marrow health. Active clinical trials are investigating whether nedosiran can actually help dissolve existing oxalate crystals in patients who already have systemic oxalosis. Additionally, novel delivery systems and potential combination therapies with other siRNA medications are being studied to provide even more effective oxalate suppression for patients with the rarest forms of the disease.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Genetic Testing: To confirm the diagnosis of Primary Hyperoxaluria Type 1.
• 24-Hour Urinary Oxalate: To establish a baseline for monitoring treatment response.
• Kidney Function (eGFR): To ensure the patient meets the criteria for therapy.
• Baseline Liver Tests: To monitor for any changes during treatment.

Precautions during treatment

• Vigilance for Stone Formation: Even with treatment, patients may still pass existing stones. Monitoring for sudden flank pain or blood in the urine is essential.
• Compliance: Because nedosiran is a monthly injection, missing doses can lead to a rapid rebound in oxalate levels.

“Do’s and Don’ts” List

• DO maintain high fluid intake (hyperhydration) unless otherwise directed by your doctor.
• DO rotate your injection sites to prevent skin irritation.
• DO keep all follow-up appointments for blood and urine monitoring.
• DON’T stop the medication without consulting your hematologist or nephrologist, as oxalate levels will rise quickly.
• DON’T ignore severe pain in the back or side, which may indicate a kidney stone.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment plan.